Intravenous Antibiotic Treatment for E. coli Infection

Initial Antibiotic Selection

The American College of Emergency Physicians and the Infectious Diseases Society of America recommend piperacillin-tazobactam 4.5g IV every 6 hours as the first-line intravenous antibiotic treatment for patients with E. coli infection confirmed by PCR 1, 2
For non-critically ill patients with community-acquired infection, alternative options include ceftriaxone 2g IV daily plus metronidazole 500mg IV every 6 hours, cefotaxime 2g IV every 8 hours plus metronidazole 500mg IV every 6 hours, or ciprofloxacin 400mg IV every 8 hours plus metronidazole 500mg IV every 6 hours for patients with beta-lactam allergies 1

For patients with E. coli endocarditis, the American Heart Association recommends combination therapy with either ampicillin or a broad-spectrum cephalosporin with an aminoglycoside, usually gentamicin 3, 4
Third-generation cephalosporins, such as ceftriaxone, have shown effectiveness in experimental models of E. coli endocarditis 3, 4

The Infectious Diseases Society of America recommends treatment duration of 5-7 days for uncomplicated infections, 7-14 days for complicated infections, and 4-6 weeks for endocarditis or severe infections 1, 2, 3, 4

The Infectious Diseases Society of America recommends monitoring clinical response within 48-72 hours of initiating therapy and adjusting therapy based on culture and susceptibility results when available 1, 2
Consider source control as an essential component of treatment 1, 2

Quinolone-resistant E. coli is increasingly common, and quinolones should not be used unless local susceptibility rates exceed 90% 2